Article Contents ::
- 1 The Brand Name PROGTASE Has Generic Salt :: Leuprolide
- 2 PROGTASE Is From Company Wockhardt Priced :: Rs. Na
- 3 PROGTASE have Leuprolide is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name PROGTASE Has Generic Salt :: Leuprolide
PROGTASE Is From Company Wockhardt Priced :: Rs. Na
PROGTASE have Leuprolide is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Uterine fibroids, Endometriosis, Prostate cancer
Drug Dose ::
Recommended Dose: 1 mg (0.2 mL) administered as a single daily SC injection. The injection sites should be varied periodically. Lucrin Depot PDS: 1-Month (3.75 mg)/3-Month (11.25 mg): As with other drugs administered by injection, the injection site should be varied periodically. 1-Month (3.75 mg): Prostate Cancer, Endometriosis, Endometriosis with Add-back, Uterine Fibroids, Breast Cancer: Recommended Dose: 3.75 mg administered monthly as a single IM or SC injection. Central Precocious Puberty (CPP): The dose must be individualized for each child. The dose is based on a mg/kg ratio of Lucrin Depot PDS to body weight. Younger children require higher doses on a mg/kg ratio.
Hypersensitivity to GnRH, GnRH agonist analogs or any of the excipients Undiagnosed abnormal vaginal bleeding. The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by the drug. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Use in women who are breast-feeding. Norethindrone acetate is contraindicated in women with the following conditions: Thrombophlebitis, thromboembolic disorders, cerebral apoplexy, or a past history of these conditions Markedly impaired liver function or liver disease Known or suspected carcinoma of the breast
Drug Precautions ::
Safe use of leuprolide acetate or norethindrone acetate in pregnancy has not been established clinically. Before starting treatment with LUPRON DEPOT, pregnancy must be excluded. When used monthly at the recommended dose, LUPRON DEPOT usually inhibits ovulation and stops menstruation. Contraception is not insured, however, by taking LUPRON DEPOT. Therefore, patients should use non-hormonal methods of contraception. Patients should be advised to see their physician if they believe they may be pregnant. If a patient becomes pregnant during treatment, the drug must be discontinued and the patient must be apprised of the potential risk to the fetus. During the early phase of therapy, sex steroids temporarily rise above baseline because of the physiologic effect of the drug. Therefore, an increase in clinical signs and symptoms may be observed during the initial days of therapy, but these will dissipate with continued therapy. Norethindrone acetate treatment should be discontinued if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be withdrawn.
Drug Side Effects ::
The following adverse reactions are commonly associated with the pharmacological actions of leuprorelin acetate on steroidogenesis: Men: Benign, Malignant and Unspecified Neoplasm (Including Cysts and Polyps): Prostate tumor flare, aggravation of prostate cancer. Metabolism and Nutrition Disorders: Weight gain/loss. Psychiatric Disorders: Loss or decreased libido, increased libido. Nervous System Disorders: Headache, muscular weakness. Vascular Disorders: Vasodilatation, hot flushes, hypotension, orthostatic hypotension. Skin and Subcutaneous Tissue Disorders: Dry skin, hyperhydrosis, rash, urticaria, abnormal hair growth, hair disorder, night sweats, hypotrichosis, pigmentation disorder, cold sweats, hirsutism. Reproductive System and Breast Disorders: Gynaecomastia, breast tenderness, erectile dysfunction, testicular pain, breast enlargement and pain, prostate pain, penile swelling, penis disorder, testis atrophy. General Disorders and Administration Site Conditions: Mucosal dryness. Investigations: Increased PSA, decreased bone density. Long Exposure (6-12 Months): Diabetes mellitus, impaired glucose tolerance, osteoporosis; increased total cholesterol, low-density lipoprotein and triglycerides.
Pregnancy category ::
Drug Mode of Action ::
Leuprorelin is a gonadotropin-releasing hormone (GnRH) analogue. Following an initial stimulation of gonadotrophins, continuous admin of Leuprorelin leads to down regulation of GnRH receptors and subsequently reduces pituitary gonadotrophin secretion. Reduced gonadotrophin levels lead to inhibition of sex hormone (testosterone and oestrogen) production. Within 2-4 wk after treatment initiation, testosterone levels in male may be reduced to below castrate threshold.
Drug Interactions ::